Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (497)	10/23/1998 2:17:00 PM
From: Gerald Walls	Read Replies (3) \| Respond to of 857

I appreciate that they don't "prove" anything, one way or the other, about the drug but, nevertheless, they are certainly remarkable and not without value. I hope the FDA seriously takes such episodes into consideration for early approval, especially since there does not seem to be any substantive downside for the patients. The FDA doesn't work that way. Look at the vitamin industry. They can't make a single claim on their bottles that haven't been proven or the FDA nails them. And this is just for preventative applications, let alone a claim to actually cure a disease.

To: Marty who wrote (497)	10/24/1998 1:11:00 PM
From: Cavalry	Respond to of 857

the downside factor is key point, what i found in my ampligen research was that in canadien tests, the length of each treatment varied between doctors. the length of each treatment ideally was 1/2 hour. read one patient who had negative reactions to ampligen reived his treatments in one hour durations not proper 1/2 hour, seems by slowing down speed of iv causes soreness and discomfort. olsten administering tests will turn out to be big plus for heb, i didnt realize olsten agreed to lay out money to purchase the supply of ampligen they will be administering, lot of choice info re alliances heb has in sec filing from 8/17, most of those alliances entail a way to produce massive amounts of ampligen at far lower costs to meet expected future world wide demand for ampligen. cav